Doug Hulse

Mr. Hulse is the Founding Chief Executive Officer of BCI Life Sciences. He has been a Principal and Executive Director at The Sage Group, as well as a Co-Managing Principal at Select BioVentures. He has over fifty years experience building new businesses based on new technology, either in a deal-making or operating role, in the areas of biopharmaceuticals and the chemical process industries. While an Executive Director of The Sage Group, he served as President and Chief Operating Officer of Hemispherx Biopharma, a public biotechnology company in Philadelphia developing novel double stranded RNA therapeutics.

Before joining the Sage Group, he built the business development activity at Enzon, Inc., an emerging biopharmaceutical company exploiting proprietary drug delivery technologies and a leading company in protein replacement therapies, as a consultant and later as Vice President of Business Development. Mr. Hulse completed over 30 deals, including the acquisition of Genex Corporation, in his last three years at Enzon.

Prior to joining Enzon, Mr. Hulse specialized in biomedical and advanced materials start-ups, serving as Founder and Chief Executive Officer for growth companies such as i-STAT Corporation, Sunstone, Inc., Envirometrics and Polycyclose Technologies, as well as an environmental process firm, SDTX Technologies.